Compounds > 3-nitrobenzeneboronic acid
Page last updated: 2024-11-04

3-nitrobenzeneboronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1677
CHEMBL ID20945
SCHEMBL ID127723
SCHEMBL ID14071499
MeSH IDM0068413

Synonyms (71)

Synonym
AC-5363
3-nitrobenzeneboronic acid
13331-27-6
boronic acid, (3-nitrophenyl)-
nsc-59739
3-nitrophenylboronic acid ,
benzeneboronic acid, m-nitro-
nsc59739
m-nitrophenylboronic acid
wln: wnr cbqq
m-nitrobenzeneboronic acid
nsc 59739
brn 2938638
ai3-60393
(3-nitrophenyl)boronic acid
nsc-401539
nsc401539
DB02797
3-nitrophenylboronic acid, >=97%
NCGC00092010-01
STK503722
m-nitophenyl boronic acid
3-nitrophenyl boronic acid
CHEMBL20945 ,
AKOS000265274
FT-0659121
N0563
bdbm50067887
3-nitro-phenyl-1-dihydroxyborane
A806593
(3-nitrophenyl)boronic acid;3-nitrophenylboronic acid
NCGC00092010-02
(3-nitrophenyl)-boronic acid
EN300-54327
boronic acid, b-(3-nitrophenyl)-
meta-nitrobenzeneboronic acid
unii-jlc765w4pn
jlc765w4pn ,
FT-0645343
FT-0602438
AS-2715
AM20060323
AB00854
SCHEMBL127723
3-nitropenyl boronic acid
m-nitrophenyl boronic acid
3-nitrobenzene-boronic acid
3-nitro-phenylboronic acid
dihydroxy(3-nitrophenyl)borane
ZNRGSYUVFVNSAW-UHFFFAOYSA-N
3-nitrobenzene boronic acid
3-nitro phenyl boronic acid
3-nitrophenyl-boronic acid
meta-nitrophenylboronic acid
3-nitro benzene boronic acid
3-nitro-phenyl boronic acid
SCHEMBL14071499
DTXSID2065416
mfcd00007193
SY015120
J-512975
CS-W007413
F0001-0442
BBL104406
BCP18407
Q27093741
3-nitro phenylboric acid
PD007633
Z808609458
HY-W007413
3(nitrophenyl)boronic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency8.91250.000811.382244.6684AID686978
67.9K proteinVaccinia virusPotency2.51190.00018.4406100.0000AID720579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chymotrypsinogen ABos taurus (cattle)IC50 (µMol)200.00000.98004.05607.2000AID36989
Beta-lactamaseEscherichia coli K-12IC50 (µMol)5.00000.01502.46578.0000AID38396
Beta-lactamaseEscherichia coli K-12Ki1.70000.02703.64137.3000AID38397; AID38398
Trypsin-2Homo sapiens (human)IC50 (µMol)200.00000.00351.58464.4000AID44381
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)200.00000.00031.38338.4000AID36989
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)200.00000.00051.48357.8000AID36989
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)IC50 (µMol)200.00000.00311.73607.8000AID36989
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)IC50 (µMol)200.00000.00501.79627.8000AID36989
Angiotensin-converting enzymeRattus norvegicus (Norway rat)Ki1.70000.00011.96427.3000AID38398
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
digestionChymotrypsinogen ABos taurus (cattle)
antibiotic catabolic processBeta-lactamaseEscherichia coli K-12
response to antibioticBeta-lactamaseEscherichia coli K-12
proteolysisTrypsin-2Homo sapiens (human)
digestionTrypsin-2Homo sapiens (human)
antimicrobial humoral responseTrypsin-2Homo sapiens (human)
extracellular matrix disassemblyTrypsin-2Homo sapiens (human)
positive regulation of cell growthTrypsin-2Homo sapiens (human)
collagen catabolic processTrypsin-2Homo sapiens (human)
positive regulation of cell adhesionTrypsin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingChymotrypsinogen ABos taurus (cattle)
serpin family protein bindingChymotrypsinogen ABos taurus (cattle)
beta-lactamase activityBeta-lactamaseEscherichia coli K-12
hydrolase activityBeta-lactamaseEscherichia coli K-12
metalloendopeptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-2Homo sapiens (human)
calcium ion bindingTrypsin-2Homo sapiens (human)
protein bindingTrypsin-2Homo sapiens (human)
serine-type peptidase activityTrypsin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionChymotrypsinogen ABos taurus (cattle)
serine protease inhibitor complexChymotrypsinogen ABos taurus (cattle)
outer membrane-bounded periplasmic spaceBeta-lactamaseEscherichia coli K-12
periplasmic spaceBeta-lactamaseEscherichia coli K-12
extracellular regionTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular matrixTrypsin-2Homo sapiens (human)
azurophil granule lumenTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID1862382Synergistic antibacterial activity against KPC-2 producing Escherichia coli BL21 (DE3) assessed as cefotaxime MIC at 5 ug/ml incubated for 16 to 20 hrs by microdilution method (Rvb = 16 ug/ml)2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID67675Compound was tested for its specificity against Elastase1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
AID1862380Synergistic antibacterial activity against KPC-2 producing Escherichia coli BL21 (DE3) assessed as cefotaxime MIC at 50 ug/ml incubated for 16 to 20 hrs by microdilution method (Rvb = 16 ug/ml)2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID1862376Inhibition of bacterial beta-lactamase KPC-2 expressed in Escherichia coli BL21 (DE3) using nitrocefin as substrate assessed as inhibition constant by Cheng-Prusoff equation analysis2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID1862393Cytotoxicity against HEK293 cells assessed as cell viability at 5 to 50 ug/ml incubated for 24 hrs in presence of cefotaxime by MTT assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID1862377Acid dissociation constant, pKa of the compound in 0.1 M phosphate buffer at 0.1 mM at pH 4.3 to 10.9 by UV-visible spectrophotometric analysis2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID38397Binding affinity towards AmpC beta-lactamase binding site from Escherichia coli2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Structure-based approach for binding site identification on AmpC beta-lactamase.
AID1862386Antibacterial activity against Escherichia coli assessed as bacterial growth inhibition at 5 to 50 ug/ml incubated for 16 to 20 hrs by microdilution method2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID1862381Synergistic antibacterial activity against KPC-2 producing Escherichia coli BL21 (DE3) assessed as meropenem MIC at 50 ug/ml incubated for 16 to 20 hrs by microdilution method (Rvb = >= 64 ug/ml)2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID1862379Antibacterial activity against Escherichia coli NCTC104182022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID482996Inhibition of AmpC beta lactamase by spectrophotometry2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase inhibitors.
AID227937Binding constant with catechol dye alizarin red S in 0.1 M PBS buffer at the pH=7.52004Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1
3-Methoxycarbonyl-5-nitrophenyl boronic acid: high affinity diol recognition at neutral pH.
AID1497005Inhibition of bacterial beta-lactamase KPC2 expressed in Escherichia coli BL21(DE3) assessed as potentiation of cefotaxime--induced inhibition of bacterial growth 50 ug/disc after overnight incubation by disk diffusion method2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Boronic acid inhibitors of the class A β-lactamase KPC-2.
AID437825Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X assessed as residual activity at 1000 uM preincubated for 60 mins before addition of substrate mixture of (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid and 5,5'-dithiobis(2-nitroben2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors.
AID1497004Inhibition of bacterial beta-lactamase KPC-22018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Boronic acid inhibitors of the class A β-lactamase KPC-2.
AID1862383Synergistic antibacterial activity against KPC-2 producing Escherichia coli BL21 (DE3) assessed as meropenem MIC at 5 ug/ml incubated for 16 to 20 hrs by microdilution method (Rvb = >= 64 ug/ml)2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID437817Inhibition of Actinomadura sp. R39 penicillin-binding protein assessed as residual activity at 1000 uM preincubated for 60 mins before addition of substrate mixture of (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid and 5,5'-dithiobis(2-nitrobenzoic ac2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors.
AID1497003Inhibition of bacterial AmpC2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Boronic acid inhibitors of the class A β-lactamase KPC-2.
AID1497000Inhibition of beta-lactamase CMY-4 in Escherichia coli G69 assessed as cefotaxime MIC at 50 ug/ml incubated for 16 hrs by broth microdilution method (Rvb >32 ug/ml)2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Boronic acid inhibitors of the class A β-lactamase KPC-2.
AID38396Compound was tested for its specificity against AmpC beta-lactamase1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
AID38398Inhibitory activity against Escherichia coli AmpC beta-lactamase.1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
AID1862384Dissociation constant, pKa of the compound in 0.1 M phosphate buffer by UV-visible spectrophotometer2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID1496997Effect on growth of Escherichia coli BL21(DE3) at 50 ug/disk after overnight incubation by disk diffusion method2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Boronic acid inhibitors of the class A β-lactamase KPC-2.
AID1497001Inhibition of NDM-1 in Klebsiella pneumoniae NCTC 13443 assessed as cefotaxime MIC at 50 ug/ml incubated for 16 hrs by broth microdilution method (Rvb >32 ug/ml)2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Boronic acid inhibitors of the class A β-lactamase KPC-2.
AID1862374Potentiation of cefotaxime induced antibacterial activity against Escherichia coli BL21 (DE3) expressing pET30a KPC-2C plasmid assessed as increase in clearance zone of inhibition incubated for 16 to 18 hrs by CLSI based disc diffusion assay (Rvb = 18.5 +2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID437828Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X assessed as residual activity at 1000 uM preincubated for 4 hrs before addition of substrate mixture of (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid and 5,5'-dithiobis(2-nitroben2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors.
AID1496999Inhibition of bacterial beta-lactamase KPC2 expressed in Escherichia coli BL21(DE3) assessed as cefotaxime MIC at 50 ug/ml incubated for 16 hrs by broth microdilution method (Rvb = 16 ug/ml)2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Boronic acid inhibitors of the class A β-lactamase KPC-2.
AID44381Compound was tested for its specificity against beta-trypsin1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
AID1496998Potentiation of cefotaxime-induced antibacterial activity against Escherichia coli NCTC 10118 assessed as cefotaxime MIC after 16 hrs by broth microdilution technique (Rvb <=0.03 ug/ml)2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Boronic acid inhibitors of the class A β-lactamase KPC-2.
AID1862392Cytotoxicity against HEK293 cells assessed as cell viability at 5 to 50 ug/ml incubated for 24 hrs by MTT assay relative to control2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID1497006Inhibition of bacterial beta-lactamase KPC2 expressed in Escherichia coli BL21(DE3) assessed as reduction in cefotaxime MIC at 50 ug/ml incubated for 16 hrs by broth microdilution method relative to untreated control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Boronic acid inhibitors of the class A β-lactamase KPC-2.
AID1497002Inhibition of Beta-lactamase CTX-M in Klebsiella pneumoniae isolate 342 assessed as cefotaxime MIC at 50 ug/ml incubated for 16 hrs by broth microdilution method (Rvb >32 ug/ml)2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Boronic acid inhibitors of the class A β-lactamase KPC-2.
AID1862385Antibacterial activity against Staphylococcus aureus assessed as bacterial growth inhibition at 5 to 50 ug/ml incubated for 16 to 20 hrs by microdilution method2022European journal of medicinal chemistry, Oct-05, Volume: 240Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance.
AID36989Compound was tested for its specificity against alpha-chymotrypsin1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (11.54)18.7374
1990's3 (11.54)18.2507
2000's9 (34.62)29.6817
2010's9 (34.62)24.3611
2020's2 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.58 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ethylene glycol
Ethylene Glycol: A colorless, odorless, viscous dihydroxy alcohol. It has a sweet taste, but is poisonous if ingested. Ethylene glycol is the most important glycol commercially available and is manufactured on a large scale in the United States. It is used as an antifreeze and coolant, in hydraulic fluids, and in the manufacture of low-freezing dynamites and resins.. ethanediol : Any diol that is ethane or substituted ethane carrying two hydroxy groups.. ethylene glycol : A 1,2-glycol compound produced via reaction of ethylene oxide with water.		2.0410ethanediol;
glycol		metabolite;
mouse metabolite;
solvent;
toxin
catechol
[no description available]		2.3110catecholsallelochemical;
genotoxin;
plant metabolite
glycine
[no description available]		1.9710alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
propylene glycol
Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.. propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze.		2.0410glycol;
propane-1,2-diols		allergen;
human xenobiotic metabolite;
mouse metabolite;
protic solvent
benzo(b)thiophene-2-boronic acid
benzo(b)thiophene-2-boronic acid: inhibits AmpC beta-lactamase; structure in first source		2.7130
galactose
galactopyranose : The pyranose form of galactose.		2.4820D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
cloxacillin
Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.		2.0110penicillin allergen;
penicillin;
semisynthetic derivative		antibacterial agent;
antibacterial drug
uridine triphosphate
Uridine Triphosphate: Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.		2.0410pyrimidine ribonucleoside 5'-triphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
cytidine triphosphate
Cytidine Triphosphate: Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety.		2.0410cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
n-pentanol
n-pentanol: RN given refers to parent cpd. pentan-1-ol : A short-chain primary fatty alcohol that is pentane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It has been isolated from Melicope ptelefolia.		2.0210pentanol;
short-chain primary fatty alcohol		human metabolite;
plant metabolite
boric acid
[no description available]		2.0110boric acidsastringent
pentane
Pentanes: Five-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives.. pentane : A straight chain alkane consisting of 5 carbon atoms.		2.0210alkane;
volatile organic compound		non-polar solvent;
refrigerant
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		2.0210cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
thiazolidines
Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.		2.0710thiazolidine
fucose
Fucose: A six-member ring deoxysugar with the chemical formula C6H12O5. It lacks a hydroxyl group on the carbon at position 6 of the molecule.. L-fucopyranose : The pyranose form of L-fucose.. fucose : Any deoxygalactose that is deoxygenated at the 6-position.		2.3110fucopyranose;
L-fucose		Escherichia coli metabolite;
mouse metabolite
diphenylborinic acid
diphenylborinic acid: structure given in first source		1.9910
n-butylboronic acid
[no description available]		1.9910
acetylglucosamine
Acetylglucosamine: The N-acetyl derivative of glucosamine.. N-acetyl-beta-D-glucosamine : An N-acetyl-D-glucosamine having beta-configuration at the anomeric centre.		2.3110N-acetyl-D-glucosamineepitope
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		2.4320dihydrogen
rhamnose
[no description available]		2.3110L-rhamnose
moxalactam
Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.. moxalactam : A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents.		2.0110cephalosporin;
oxacephem		antibacterial drug
phenylethane boronic acid
[no description available]		2.0510
benzeneboronic acid
[no description available]		3.2760boronic acids
fructose-6-phosphate
fructose-6-phosphate: RN given refers to parent cpd with unspecified isomeric designation. fructose 6-phosphate : A ketohexose monophosphate consisting of fructose having a phosphate group located at the 6-position.		2.2110D-fructose 6-phosphate
4-bromophenylboric acid
[no description available]		1.9910
3-aminobenzeneboronic acid
[no description available]		3.2860
1,2-pentanediol
[no description available]		2.0210
carbapenems
[no description available]		2.0710
xylose
xylopyranose: structure in first source		2.3110D-xylose
n-dansyl-3-aminobenzeneboronic acid
N-dansyl-3-aminobenzeneboronic acid: potent serine protease inhibitor; fluorescent boronic acid which reversibly binds to bacterial cell walls; structure given in first source		2.4220
1,1'-biphenyl-4-yl-boronic acid
[no description available]		2.5220
4-methoxyphenylboronic acid
4-methoxyphenylboronic acid: structure in first source		1.9910
1,4-phenylenebis(boronic acid)
1,4-phenylenebis(boronic acid): structure in first source		1.9910
2-formylphenylboronic acid
2-formylphenylboronic acid: structure in first source		1.9910
1-hydroxy-2,1-benzoxaborole
1-hydroxy-2,1-benzoxaborole : A member of the class of benzoxaboroles that is 2,1-benzoxaborole in which the hydrogen attached to the boron atom is replaced by a hydroxy group.		2.0510benzoxaborole
arabinose
[no description available]		2.3110L-arabinoseEscherichia coli metabolite;
mouse metabolite
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		2.4110alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
thiophene-3-boronic acid
thiophene-3-boronic acid: structure in first source		1.9910
D-fructopyranose
[no description available]		2.3110cyclic hemiketal;
D-fructose;
fructopyranose		sweetening agent
alizarin red s
Alizarin Red S: RN given refers to parent cpd; structure. alizarin red S : An organic sodium salt having 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate as the counterion. It is commonly used to stain embryo skeletons in cleared whole mounts, usually of small mammals.		2.110organic sodium salt;
organosulfonate salt		histological dye
ly 163892
loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.		2.0110carbacephem;
zwitterion		antibacterial drug;
antimicrobial agent
ceftazidime
[no description available]		2.0110cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cefotaxime
Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.		2.41101,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
dizocilpine maleate
Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.		2.0410maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
ribose
ribopyranose : The pyranose form of ribose.		2.3110D-ribose;
ribopyranose
oligonucleotides
[no description available]		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.2110
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.2110
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.4620
Disease Exacerbation
[description not available]		02.0110
Cancer of Prostate
[description not available]		02.0110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0110
Classic Galactosemia
[description not available]		02.0410
Galactosemias
A group of inherited enzyme deficiencies which feature elevations of GALACTOSE in the blood. This condition may be associated with deficiencies of GALACTOKINASE; UDPGLUCOSE-HEXOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; or UDPGLUCOSE 4-EPIMERASE. The classic form is caused by UDPglucose-Hexose-1-Phosphate Uridylyltransferase deficiency, and presents in infancy with FAILURE TO THRIVE; VOMITING; and INTRACRANIAL HYPERTENSION. Affected individuals also may develop MENTAL RETARDATION; JAUNDICE; hepatosplenomegaly; ovarian failure (PRIMARY OVARIAN INSUFFICIENCY); and cataracts. (From Menkes, Textbook of Child Neurology, 5th ed, pp61-3)		02.0410